INFI Infinity Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INFI

Price (delayed)

$0.1801

Market cap

$16.19M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.48

Enterprise value

-$9.54M

Infinity Pharmaceuticals, Inc. ('Infinity' or the 'Company'), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of ...

Highlights
INFI's debt has dropped by 79% year-on-year and by 49% since the previous quarter
The company's gross profit rose by 31% YoY and by 3% QoQ
Infinity Pharmaceuticals's quick ratio has shrunk by 54% YoY and by 19% QoQ
The company's equity fell by 49% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.infi.com
Peers: CRIS PFE SGEN AMGN

Key stats

What are the main financial stats of INFI
Market
Shares outstanding
89.9M
Market cap
$16.19M
Enterprise value
-$9.54M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
6.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-3.57
Earnings
Revenue
$2.67M
EBIT
-$42.8M
EBITDA
-$42.36M
Free cash flow
-$41.47M
Per share
EPS
-$0.48
Free cash flow per share
-$0.46
Book value per share
-$0.32
Revenue per share
$0.03
TBVPS
$0.33
Balance sheet
Total assets
$29.95M
Total liabilities
$58.27M
Debt
$164,000
Equity
-$28.32M
Working capital
$17.07M
Liquidity
Debt to equity
-0.01
Current ratio
2.51
Quick ratio
2.29
Net debt/EBITDA
0.61
Margins
EBITDA margin
-1,585.2%
Gross margin
100%
Net margin
-1,608.5%
Operating margin
-1,644.6%
Efficiency
Return on assets
-92.6%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-229.3%
Return on sales
-1,601.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INFI stock price

How has the Infinity Pharmaceuticals stock price performed over time
Intraday
-1.1%
1 week
18.1%
1 month
5.94%
1 year
-71.86%
YTD
-67.55%
QTD
12.56%

Financial performance

How have Infinity Pharmaceuticals's revenue and profit performed over time
Revenue
$2.67M
Gross profit
$2.67M
Operating income
-$43.94M
Net income
-$42.98M
Gross margin
100%
Net margin
-1,608.5%
The company's gross profit rose by 31% YoY and by 3% QoQ
The revenue has grown by 31% year-on-year and by 3% since the previous quarter
INFI's net margin is up by 29% year-on-year and by 6% since the previous quarter
INFI's operating margin is up by 27% YoY and by 4.9% QoQ

Growth

What is Infinity Pharmaceuticals's growth rate over time

Valuation

What is Infinity Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
6.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-3.57
Infinity Pharmaceuticals's EPS has increased by 8% YoY and by 4% QoQ
The company's equity fell by 49% QoQ
INFI's P/S is 87% below its 5-year quarterly average of 47.7 and 74% below its last 4 quarters average of 23.1
The revenue has grown by 31% year-on-year and by 3% since the previous quarter

Efficiency

How efficient is Infinity Pharmaceuticals business performance
INFI's return on assets has dropped by 78% year-on-year and by 19% since the previous quarter
Infinity Pharmaceuticals's return on sales has increased by 29% YoY and by 6% QoQ

Dividends

What is INFI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INFI.

Financial health

How did Infinity Pharmaceuticals financials performed over time
Infinity Pharmaceuticals's total assets is 49% less than its total liabilities
Infinity Pharmaceuticals's total assets has plunged by 59% YoY and by 29% from the previous quarter
Infinity Pharmaceuticals's quick ratio has shrunk by 54% YoY and by 19% QoQ
INFI's debt is 101% greater than its equity
The debt to equity has plunged by 113% YoY but it has soared by 50% from the previous quarter
INFI's debt has dropped by 79% year-on-year and by 49% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.